Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Maternal influenza, tetanus toxoid vax not tied to infant hospitalizations, deaths

28 Feb 2018

Maternal influenza and Tdap (tetanus toxoid, reduced diphtheria toxoid, acellular pertussis) vaccinations during pregnancy do not increase the risk for hospitalization or death in infants, a study has shown.

“We found no increased risk of infant all-cause hospitalizations, hospitalizations from respiratory causes, or all-cause mortality in the first 6 months of life,” said the researchers led by Dr Lakshmi Sukumaran from the Centers for Disease Control and Prevention in Atlanta, Georgia, US. Vaccination during pregnancy was defined in the study as a jab given from 7 days after the start of pregnancy to 7 days before the end of pregnancy.

Long-term data on infants born to mothers administered influenza and Tdap vaccines have been lacking. The current study was the first to look at infant hospitalizations and mortality in the first 6 months of life after influenza and Tdap vaccines administration in mothers.

Of 413,034 infants involved in the study, 25,222 were hospitalized (4,644 were due to a respiratory cause, 105 from influenza, 137 because of pertussis) during the first 6 months of life; 157 died from unknown causes, sudden infant death syndrome, or certain conditions originating in the perinatal period.

However, there was no association between infant hospitalization and maternal influenza vaccination (adjusted odds ratio [adjOR], 1.00, 95 percent confidence interval [CI], 0.96–1.04) or Tdap vaccination (adjOR, 0.94, 95 percent CI, 0.88–1.01). There was also no link between infant mortality and maternal influenza (adjOR, 0.96, 95 percent CI, 0.54–1.69) or Tdap (adjOR, 0.44, 95 percent CI, 0.17 - 1.13) vaccinations.

The researchers said the current study supports the safety of influenza and pertussis vaccinations during pregnancy for both the mothers and their babies.

 

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.